TroFuse-005: what clinicians are saying
sacituzumab tirumotecan in endometrial cancer after platinum-based chemotherapy and immunotherapy · NCT06132958 ↗ · Phase 3 · Merck Sharp & Dohme LLC
A speaker described in the sources as presenting TroFuse-005 endorses routine sac-TMT use today, citing survival benefit they consider clinically meaningful, but a medical oncologist wants longer-term safety evidence before wider use. That caution reflects increased severe treatment-related toxicity. Conflicting authorization accounts leave current approval and funded access unclear.
Created with AI · how we check it
- edition 1
- commentary checked Nov 12, 2026
- 222 verified statements
This edition $1,250, with MCP access for your AI agent. Get this report
6 findings, and what sits behind each
01. One interview calls sac-TMT a current standard of care; clinical accounts qualify broad adoption
5 of 22 cited clinicians · 14 statements from 8 speakers in 9 sources, 1 of them a podcast or video · 9 passages
Limitations recorded: 2.
Draws on: Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR), Primary endpoint: Overall Survival (OS), Safety and tolerability, Secondary endpoints, Design and conduct.
02. Clinical accounts weigh survival gains against greater toxicity; one episode links manageability to prevention
5 of 22 cited clinicians · 18 statements from 6 speakers in 13 sources, 2 of them podcasts or videos · 21 passages
Limitations recorded: 2.
Draws on: Safety and tolerability, Secondary endpoints, Primary endpoint: Overall Survival (OS), The comparison.
03. Clinical accounts ask who should receive sac-TMT and how to sequence it with other ADCs
2 of 22 cited clinicians · 9 statements from 3 speakers in 6 sources, 1 of them a podcast or video · 7 passages
Limitations recorded: 3.
Draws on: Population and setting, Safety and tolerability, Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR), Primary endpoint: Overall Survival (OS).
04. One speaker defends the chemotherapy comparator; other accounts stress evidence maturity
5 of 22 cited clinicians · 13 statements from 6 speakers in 9 sources, 2 of them podcasts or videos · 11 passages
Limitations recorded: 3.
Draws on: Design and conduct, The comparison, Population and setting, Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR), Secondary endpoints, Safety and tolerability.
05. Accounts distinguish clinical enthusiasm from authorization and access
No named clinician · accounts and unnamed speakers · 15 statements from 3 speakers in 11 sources, 4 of them podcasts or videos · 12 passages
Limitations recorded: 3.
Draws on: Design and conduct.
06. Speakers explain sac-TMT through targeted-delivery analogies; one report cautions against cure expectations
3 of 22 cited clinicians · 14 statements from 3 speakers in 6 sources, 5 of them podcasts or videos · 12 passages
Limitations recorded: 3.
Draws on: Secondary endpoints, Safety and tolerability.
Counts overlap, since one statement can back several findings. They show what the report kept, not how many clinicians agree. The full report includes the interpretations and source links.
Select a finding to see what the full report holds for it. Select a part of the trial to see which findings draw on it.
- Finding 1 of 6
5 of 22 cited clinicians
One interview calls sac-TMT a current standard of care; clinical accounts qualify broad adoption
14 statements from 8 speakers in 9 sources, 1 of them a podcast or video
- 14
- statements
- 9
- passages
- 9
- sources
- 8
- speakers
What the statements areViews 10Questions and uncertainty 1Clinical experience 0Comparisons 1Restated results and context 2Statement-to-passage links (a passage can back several statements)Supporting a statement 14Giving context 1Recorded with the findingLimitations: 2
8 posts and articles · 1 podcast or video
Draws on: Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR), Primary endpoint: Overall Survival (OS), Safety and tolerability, Secondary endpoints, Design and conduct.
Thicker lines mean more shared statements. A finding without a line goes beyond the registered design. Counts overlap: one statement can back several findings.
The full report also has 7 findings about other patients, lines of treatment or settings, after these trial findings under “Beyond the trial population”. They are not counted or listed on this page.
Medical oncologist · ex-US
Post on LinkedIn · Oct 2026
Staff page checked · finding 1
A medical oncologist considers longer-term safety, biomarker analyses and optimal treatment sequencing essential before widespread adoption of sacituzumab tirumotecan in this setting.
Statements as the report records them, by the speaker's role only. Full statements, speaker names and links to each source are in the report.
Abbreviations (8)
ADC, antibody–drug conjugate; BICR, blinded independent central review; HCP, healthcare professional; MCP, Model Context Protocol, how AI agents read the report; NPI, National Provider Identifier, the US registry number for clinicians; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.
The full TroFuse-005 report gives each finding its interpretation, the attributed views behind it, counterviews, limits and the verified statements, each linked to the original. One report in the catalog, IDeate-Lung01, is free in full, so you can see what a paid report holds before you buy: read the free IDeate-Lung01 report.
What do clinicians say they still need to see on longer-term safety, biomarker analyses, subgroup results and treatment sequencing before broadly adopting sacituzumab tirumotecan for recurrent endometrial cancer after platinum chemotherapy and immunotherapy?
From finding F1 (14 statements from 8 speakers in 9 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.
By the numbers
- 160commentary sources screened
- 72sources cited by verified statements
- 37named in screened sources
- 35speakers cited in the report
- 26cited speakers with a verified identity
22 cited clinicians, speakers with a confirmed clinical role, of them 22 physicians. By role and specialty:
- 9 physician, Medical oncology
- 8 physician, Surgical oncology
- 3 physician, specialty not confirmed
- 1 physician, Gynecologic oncology
- 1 physician, Pathology
Also in the sources: 21 organizational or shared accounts, not counted as people.
- 222verified statements, each linked to its source
- 66of them from speakers with a confirmed clinical role
- 6findings
Built by AI from public clinician commentary, checked by automated review; every statement links to its source.
A cited clinician is a cited speaker whose clinical role the NPI registry or their own institution's staff page confirms; a role a source only states is not counted. A verified identity says who a speaker is, with or without such a role. Physicians are clinicians whose confirmed role is a physician's.
Counts show what the report kept, not how many clinicians hold a view. Size is set by the verified statements; Standard and Deep need 5 or more cited clinicians. Statements from sponsors, hosts and organisations are labelled and count apart.
What's inside
| Section | Items | Access |
|---|---|---|
| Findings with interpretation, counterviews and limits | 6 | Titles free |
| Detailed analysis | 16 sections | Paid |
| Verified statements with short source quotes and links | 222 | Paid |
| Who said each statement: the cited speakers | 35 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 22 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 26 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 11 | Free |
| Sources with links | 72 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |
Every edition names who said each statement, with MCP access for your AI agent. Each verified speaker comes with their verified IDs (NPI, ORCID, staff page) so your team can check each attribution. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
Trial aspects
11 discussed · 0 no commentary found · 0 assessment incomplete| Aspect | Statements | Sources |
|---|---|---|
| Primary endpoint: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR) | 20 | 18 |
| Primary endpoint: Overall Survival (OS) | 20 | 16 |
| Secondary endpoints | 15 | 13 |
| Population and setting | 25 | 14 |
| The comparisonThe registered arms and what clinicians said about how they compare. | 9 | 7 |
| Safety and tolerability | 30 | 21 |
| Design and conduct | 13 | 8 |
| Clinical positioning and strength of endorsement | 51 | 37 |
| Patient selection, subgroup uncertainty and ADC sequencing | 12 | 9 |
| Authorization, funding, access and clinical-trial discussion | 20 | 12 |
| Targeted-delivery rationale and earlier disease-specific sac-TMT evidence | 25 | 12 |
Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.
Sources
222 verified statements from 72 cited sources. A video or podcast is one source but often carries many statements, so the table counts statements, not just posts.
| Channel | Statements | Cited | Screened | |
|---|---|---|---|---|
| Video & audio · 122 statements · 55%from 16 videos and episodes · about 8 per source | ||||
| YouTube | 68 | 7 | 7 | |
| Podcasts | 54 | 9 | 9 | |
| Posts · 95 statements · 43%from 54 posts · about 2 per source | ||||
| X threads | 67 | 42 | 117 | |
| LinkedIn posts | 19 | 8 | 10 | |
| Bluesky threads | 9 | 4 | 17 | |
| Primary sources · 5 statements · 2%cited for context, not screened · from 2 sources · about 3 per source | ||||
| Publications | 4 | 1 | — | |
| Registry | 1 | 1 | — | |
Screened: found and read for this trial. Cited: backs at least one statement. Bar = statements; a statement drawn from two sources counts half to each. How we sourced and checked this
max 121 / quarter
- Screened window
- Apr 5, 2024 → Nov 5, 2026
- Cited window
- May 1, 2024 → Nov 5, 2026
- Retrieved
- Nov 12, 2026
The trial
from ClinicalTrials.gov- Title
- A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
- Also known as
- ENGOT-en23, GOG-3095
- Registry
- NCT06132958
- Study IDs
- 2870-005 · 2023-504816-14-00 (EU CT) · U1111-1288-7581 (UTN) · jRCT2031240041 (Japan Registry of Clinical Trials (jRCT))
- Sponsor
- Merck Sharp & Dohme LLC
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT), GOG Foundation
- Design
- Phase 3 · Interventional, randomized, parallel
- Status
- Active, not recruiting
- Enrollment
- 710 estimated
- Registered
- 2023-11-15
- Start
- 2023-12-06 actual
- Primary completion
- 2028-01-10 estimated
- Primary endpoints
- Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Blinded Independent Central Review (BICR)
- Overall Survival (OS)
- Interventions
- 5 registered
More on: Endometrial cancer
Discussed at: ESMO Congress 2026
Scope and limits
This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.
- Not yet captured in this edition: a view on treatment history and unmet need when considering antibody–drug conjugates after chemotherapy and immunotherapy; a view on checkpoint switching versus adding lenvatinib after progression on immunotherapy in endometrial cancer; a remark on an inference explicitly qualified as an assumption without supporting data; a view on prioritizing a treatment-comparison trial in previously treated recurrent or advanced endometrial cancer.
- Discussion that does not name the trial may be missing from this edition.
- 5 matching sources (3 YouTube videos, 2 X threads) could not be read and are not included.
- 1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition.
- 333 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
Show all 18 known gaps +Fewer −
- Further source limits: 5 sources about other trials or topics are not included.
- The sources reviewed for this edition are not representative of all HCPs or all public discussion, and source totals cannot be interpreted as numbers of independent clinicians.
- Two social threads and three video transcripts were unavailable. Other passages could not be described reliably or fully: the origin of reported evidence was unclear in two, while additional material left safety qualifications, prior-treatment distinctions, an account’s prioritization or an explicit evidence limitation incompletely represented. Another passage was not fully assessed. These gaps may obscure minority positions and practical qualifications.
- The treatment-choice discussions are not exhaustive. Absence of an option or exception from this report does not show that a speaker rejected it or failed to discuss it.
- Several passages cannot be assigned to a named speaker. A guest list, program description, profile or research identity does not establish who spoke those words.
- Public accounts, organizations, investor-oriented commentary and an episode containing AI-generated content contribute some views; their inclusion does not establish clinical expertise or independent clinical endorsement.
- Earlier design and access discussions, May 2026 announcements and October–November 2026 detailed-result commentary concern different information states. Dates alone do not demonstrate a change of mind.
- Interim follow-up, unresolved subgroup and biomarker questions, limited quality-of-life detail and absent comparative sequencing evidence constrain implementation interpretations.
- Safety accounts distinguish overall adverse events, treatment-related adverse events, serious events, discontinuation and treatment-related deaths; these measures should not be merged.
- No exact sacituzumab tirumotecan label was available, and jurisdictional authorization descriptions conflict, so the report does not determine current approval or reimbursed access.
- Small retrospective rechallenge series, individual clinical experiences and subsequent-trial anecdotes do not provide direct comparative evidence against sac-TMT.
- Source-described roles and trial involvement are not independently confirmed professional appointments or proof of an external, independent assessment. Professional associations also do not establish current employment.
- The ovarian-cancer educational account is development context only. Its activity observations and corrected description of a path to Phase III are not endometrial-cancer TroFuse-005 results. Its full toxicity and supportive-care discussion is not captured here, so the account should not be used as a complete benefit–risk appraisal or evidence of comparative tolerability.
How reports are built and checked: Methods.
Editions and corrections
Routine maintenance: 3 fixes (names, counts, text)
None of these changed a statement, finding or source.
- Nov 12, 2026 UTCCorrected to match the delivered report: the question clinicians left open; per-finding counts; the limitations; the examples from the report; the abstract, which no longer repeats the open question; the report description.
- Nov 12, 2026 UTCA sentence that said more than its speaker's words was removed.
- Nov 12, 2026 UTCThe trial's name is spelled as its investigators write it, “TroFuse-005” (NCT06132958), outside quotations (was “Trofuce”).
Last checked for new commentary Nov 12, 2026 UTC. No changes. Follow new editions and changes in this report's change feed (JSON Feed), or the catalog's. How versions and corrections work.
Cite this report
Erudio Health. TroFuse-005 (NCT06132958): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 12, 2026. https://www.erudio.com/reports/trofuse-005-nct06132958
For your AI agent
Paste this into ChatGPT, Claude, Microsoft Copilot or your own agent. It previews this report through the free Erudio MCP server, tells you whether it answers your question, and orders it if you ask. Some agents ask you to confirm pasted instructions before acting; that is expected.
Help me decide whether to buy the Erudio report "TroFuse-005" (NCT06132958), and buy it for me if I ask. Erudio reports cover what clinicians say in public about one clinical trial, with every verified statement linked to its source.
1. Use the free Erudio MCP server at https://mcp.erudio.com/free; it needs no sign-in. Nothing needs installing: if it is not connected in this app and you can make HTTP requests, call it directly with JSON-RPC POSTs to that URL (initialize, then tools/call), sending "Accept: application/json, text/event-stream". Call get_report_card with slug "trofuse-005-nct06132958". If you cannot make requests, read https://www.erudio.com/reports/trofuse-005-nct06132958.md instead.
2. In a few lines, tell me what the report covers: its findings, its verified statements and sources, its evidence window, what it leaves out, and the price of each product (offer). Then ask what I need it for, and say plainly whether this report answers it.
3. If I want it, ask for my work email, my organization and the product: the current edition, or 3, 6 or 12 months of updates. Call create_order with report "NCT06132958", that product, email and organization, then show me the quote and the checkout_url to pay by card. If you have a payment client for HTTP 402 payments and I agree, you can pay the pay_url instead. Nothing is charged until one is paid.
4. Once it is paid, call get_order with the status_url: it returns my license key. Then use the Erudio MCP server at https://mcp.erudio.com/mcp with the header "Authorization: Bearer <key>". Call read_report with report_id NCT06132958 and sections ["all"], and summarize the findings for me with their sources. The full report can be long: save the response to a file and work from it rather than printing it. If you cannot, read sections ["narratives"] first, the executive summary and analysis.
When you tell me what clinicians said, give each view as theirs, with its source. Counts are the sources the report kept, not the share of clinicians who agree. Reports are not medical advice.
Keep the key private to my organization.Or read the record directly: JSON, Markdown or MCP
curl https://www.erudio.com/reports/trofuse-005-nct06132958.json
curl https://www.erudio.com/reports/trofuse-005-nct06132958.md
# MCP, no sign-in (https://mcp.erudio.com/free)
get_report_card({ "slug": "trofuse-005-nct06132958" })release eac21b48fa95ee6198488c48be4baa4b54cfb21e4611c4917bb1f6ad67d3e268
Questions
How much does the TroFuse-005 report cost?
One edition costs $1,250 (Standard · 222 verified statements · 66 from 22 confirmed clinicians). With updates: 3 months $2,200, 6 months $3,100, 12 months $4,400. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.
What does the TroFuse-005 report cover?
222 statements from 72 sources (9 podcasts, 7 videos, 54 posts, 1 paper, 1 registry record), 66 of them from 22 confirmed clinicians, each linked to its source. Commentary checked Nov 12, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.
Can my AI agent read or buy the TroFuse-005 report?
Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "trofuse-005-nct06132958" }) previews it and create_order({ "report": "NCT06132958", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. Connect your AI client.
How current is the TroFuse-005 report?
Edition 1 (version 1.0.0), accepted Nov 12, 2026 UTC; last checked for new commentary Nov 12, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.